Fig. 2.

PSADT pre- and post-DCVAC/PCa treatment and in subsequent cycles of treatment for biochemical relapse prostate cancer patients (n = 25). The PSADT value for each patient pre- and post-treatment was plotted. PSADT was significantly prolonged; on average, there was a 3.32 times increase in the median PSADT after completion of the treatment. The median PSADT prior to immunotherapy was 5.67 months and increased to 18.85 months at the completion of the first cycle of immunotherapy (a, b). PSADT remained stable during the second cycle of treatment, with a median PSADT of 58.03 months (c)